初级保健就诊时筛查老年房颤:VITAL-AF随机对照试验
1年时筛查组新发房颤诊断率为1.72%,对照组为1.59%(风险差0.13%,95%CI -0.16至0.42,P=0.38),总体无显著差异;≥85岁亚组筛查组新发房颤多于对照组(5.56% vs 3.76%,风险差1.80%,95%CI 0.18至3.30)。
要点
- 初级保健就诊时单导联心电图筛查未增加≥65岁人群总体新发房颤诊断。
- ≥85岁亚组筛查组新发房颤诊断率高于对照组。
- 筛查组与对照组新诊断房颤患者启动口服抗凝药比例无显著差异。
核心结论
- 在≥65岁初级保健就诊人群中,手持单导联心电图筛查与常规护理相比未影响1年内新发房颤诊断率。
研究设计与样本
- 筛查组在生命体征评估时使用手持单导联心电图(AliveCor KardiaMobile)进行床旁筛查,筛查结果提供给初级保健临床医生,确诊检查与治疗由临床医生决定。
- 随访1年,新发房颤诊断通过电子病历与人工裁定确认。
主要发现
- 1年时筛查组新发房颤诊断率为1.72%,对照组为1.59%,风险差0.13%(95%CI -0.16至0.42),P=0.38。
- 预设亚组分析中,≥85岁人群筛查组与对照组新发房颤诊断率分别为5.56%与3.76%,风险差1.80%(95%CI 0.18至3.30)。
- 筛查期与上一年相比的新诊断房颤差值在筛查组与对照组分别为0.32%与-0.12%,风险差0.43%(95%CI -0.01至0.84)。
- 新诊断房颤患者启动口服抗凝药比例在筛查组为73.5%(n=194),对照组为70.8%(n=172),风险差2.7%(95%CI -5.5至10.4)。
临床怎么用
- 在≥65岁初级保健就诊人群中常规使用单导联心电图筛查房颤并未显著提高总体新发房颤诊断率。
- 对≥85岁高龄人群可考虑机会性筛查,该亚组筛查组新发房颤诊断率高于对照组。
局限性
- 研究仅纳入初级保健就诊的≥65岁人群,结果外推需谨慎。
- 筛查组91%接受筛查,未完全覆盖所有随机患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Undiagnosed atrial fibrillation (AF) may cause preventable strokes. Guidelines differ regarding AF screening recommendations. We tested whether point-of-care screening with a handheld single-lead ECG at primary care practice visits increases diagnoses of AF. METHODS: We randomized 16 primary care clinics 1:1 to AF screening using a handheld single-lead ECG (AliveCor KardiaMobile) during vital sign assessments, or usual care. Patients included were ages ≥65 years. Screening results were provided to primary care clinicians at the encounter. All confirmatory diagnostic testing and treatment decisions were made by the primary care clinician. New AF diagnoses during the 1-year follow-up were ascertained electronically and manually adjudicated. Proportions and incidence rates were calculated. Effect heterogeneity was assessed. RESULTS: Of 30 715 patients without prevalent AF (n=15 393 screening [91% screened], n=15 322 control), 1.72% of individuals in the screening group had new AF diagnosed at 1 year versus 1.59% in the control group (risk difference, 0.13% [95% CI, -0.16 to 0.42]; P=0.38). In prespecified subgroup analyses, new AF diagnoses in the screening and control groups were greater among those aged ≥85 years (5.56% versus 3.76%, respectively; risk difference, 1.80% [95% CI, 0.18 to 3.30]). The difference in newly diagnosed AF between the screening period and the previous year was marginally greater in the screening versus control group (0.32% versus -0.12%; risk difference, 0.43% [95% CI, -0.01 to 0.84]). The proportion of individuals with newly diagnosed AF who were initiated on oral anticoagulants was not different in the screening (n=194, 73.5%) and control (n=172, 70.8%) arms (risk difference, 2.7% [95% CI, -5.5 to 10.4]). CONCLUSIONS: Screening for AF using a single-lead ECG at primary care visits did not affect new AF diagnoses among all individuals aged 65 years or older compared with usual care. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT03515057.
引用
- Lubitz, Atlas, Ashburner, et al. Screening for Atrial Fibrillation in Older Adults at Primary Care Visits: VITAL-AF Randomized Controlled Trial. Circulation. 2022. PMID: 35232217. doi:10.1161/CIRCULATIONAHA.121.057014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。